Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …

Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in
multiple myeloma (MM) cells, particularly in those harboring t (11; 14), which express high …

Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …

Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant
stages, such as monoclonal gammaopathy of undetermined significance and smouldering …

Purpose At the molecular level, myeloma is characterized by copy number abnormalities
and recurrent translocations into the immunoglobulin heavy chain locus. Novel methods …

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow,
leading to bone destruction and marrow failure. This manuscript discusses the management …

Therapy for multiple myeloma (MM) has markedly changed in the past decade with the
introduction of new drugs, but it is not clear whether the improvements have been sustained …

Multiple myeloma (MM) is characterized by the uncontrolled proliferation of plasma cells.
Despite recent treatment advances, it is still incurable as disease progression is not fully …

B cell activation and differentiation yields plasma cells with high affinity antibodies to a given
antigen in a time-frame that allows for host protection. Although the end product is most …